120 results about "Sicca syndrome" patented technology

The present invention provides novel pyrimidine and pyridine compounds according to Formula (I), Formula (II), Formula (III), Formula (IV) and Formula (V) their manufacture and use for the treatment of hyperproliferative diseases including, but not limited to, cancer, lupus, allergic disorders, Sjogren's disease and rheumatoid arthritis. In preferred embodiments, the present invention describes irreversible kinase inhibitors including, but not limited to, inhibitors of Bruton's tyrosine kinase.

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain substituted N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl -cyclohexyl)-4-(2-pyridyl)benzenesulfonamide compounds (collectively referred to herein as HMC compounds) that are useful, for example, in the treatment of disorders (e.g., diseases) including, inflammation and / or joint destruction and / or bone loss; disorders mediated by excessive and / or inappropriate and / or prolonged activation of the immune system; inflammatory and autoimmune disorders, for example, rheumatoid arthritis; psoriasis; psoriatic arthritis; chronic obstructive pulmonary disease (COPD); asthma; atherosclerosis; inflammatory bowel disease; ankylosing spondylitis; multiple sclerosis; systemic lupus erythematosus; Sjogren's syndrome; a disorder associated with bone loss, such as bone loss associated with excessive osteoclast activity in rheumatoid arthritis, osteoporosis, cancer-associated bone disease, or Paget's disease; cancer, such as a haematological malignancy, such as multiple myeloma, leukemia, or lymphoma, or a solid tumour cancer, such as bladder cancer, breast cancer (female and / or male), colon cancer, renal cell carcinoma, kidney cancer, lung cancer, pancreatic cancer, gastric cancer, prostate cancer, brain cancer, skin cancer, thyroid cancer, basal cell ameloblastoma, or melanoma; a disorder associated with fibrosis, such as systemic sclerosis or scleroderma; or a rare vasculitide, such as Behçet's disease. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy.

The invention discloses a traditional Chinese medicine preparation for treating sicca syndrome, solving the problem that the existing effect of treating the sicca syndrome is poor. The formula of the traditional Chinese medicine preparation comprises the following raw materials in parts by weight: 28-32 parts of raw radix astragali, 28-32 parts of radix adenophorae, 28-32 parts of dendrobium stem, 80-120 parts of reed rhizome, 13-17 parts of raw rehmannia root, 8-12 parts of dark plum fruit, 28-32 parts of spreading hedyotis herb and 28-32 parts of zedoary. The traditional Chinese medicine preparation is used for treating the sicca syndrome has brand-new composition, simple composition and pure traditional Chinese medicine, also has the functions of supplementing the vital energy, nourishing yin, promoting the production of body fluid, detoxifying, breaking blood stasis and moistening dryness, and has very good treating effect to various types of sicca syndromes without toxic and sideeffect.